Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Pharmamar S.A.
Industry Sector: HealthTechnology
CEO: José Maria Fernández de Sousa-Faro, PhD, MBA
Number Of Employees: N/A
Enterprise Value: N/A
PE Ratio: 60.54
Exchange/Ticker 1: Madrid:PHM
Exchange/Ticker 2: N/A
Latest Market Cap: $1,720,616,836
BioCentury | May 22, 2023
Deals
May 22 Quick Takes: Ironwood building GI franchise via $1B VectivBio acquisition
Plus: Krystal raises $160M PIPE and updates from Avrobio-Novartis, Avidity, BMS, Hepion, Rain, Blueprint
BioCentury | Oct 26, 2022
Finance
Oct. 26 Quick Takes: Vaxcyte prices year’s second-largest follow-on
Plus AZ’s AKT inhibitor hits co-primary endpoints in breast cancer trial, and updates from Time BioVentures, Seres, Jazz and GSK
BioCentury | Oct 19, 2022
Deals
With biliary readout looming, Jazz-Zymeworks deal could grow much larger
Jazz pays $50M up front for rights to HER2-targeting bispecific, would owe more than 6x more to retain them after first pivotal readout
BioCentury | Sep 9, 2022
Management Tracks
PATH’s Kaslow to succeed Marks as head of vaccines at FDA
Plus Apple’s Tsay becomes CMO at Cue Health, and updates from Nouscom, Deka, Cogitativo and more
BioCentury | Feb 4, 2021
Deals
Jazz strikes another chord in neuroscience via $7.2B GW pickup
With the acquisition of cannabinoid therapeutics company GW in Jazz’s largest deal ever, the company added a product and pipeline that complements its historical strength in neuroscience rather
BioCentury | Jan 30, 2021
Translation in Brief
Gladstone-UCSF research center to focus on brain diseases; plus a mammography-based prediction algorithm, PharmaMar and an intracellular glycoprotein that blocks phagocytosis
BioCentury’s roundup of translational news
BioCentury | Dec 3, 2020
Product Development
After Phase III miss, PharmaMar and Jazz may need new monotherapy trial to confirm cancer drug’s benefit
PharmaMar will likely need to conduct a new study of Zepzelca to gain its full approval after the drug failed to show a survival benefit in a potentially confirmatory Phase III trial to treat small
BioCentury | Sep 8, 2020
Management Tracks
Black Diamond names Humphrey CMO; plus Edmondson to lead chemistry at Nimbus, Recce, Amarna and more
Rachel Humphrey has joined Black Diamond Therapeutics Inc. (NASDAQ:BDTX) as CMO. Karsten Witt, who has been SVP of clinical development and acting CMO since May 2019, will become SVP of non-clinical
BioCentury | Jun 17, 2020
Product Development
June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more
BioCentury | Mar 20, 2020
Translation in Brief
Vaxxas' temperature-stable, low-dose vaccine patch; plus Stanford screen for 3-D tumor targets, new invasion mechanism for SARS-CoV-2 and PharmaMar
BioCentury’s roundup of preclinical news
Items per page:
1 - 10 of 239